With the number of US Food and Drug Administration-approved gene therapies set to balloon from fewer than 20 to about 100 by the early 2030s, the challenges of paying for them are bound to balloon as well, with total list-price spending potentially equivalent to the gross domestic products of some small countries. A recent report on the reimbursement models for gene therapies by the Institute for Clinical and Economic Review (ICER) and Tufts Medical Center’s NEWDIGS looks at the potential to combine strategies like reinsurance and rebates.
Pricing watchdog group ICER collaborated with Tufts Medical Center’s NEWDIGS (New Drug Development Paradigms) – an outcomes research-focused think tank that began in 2009 at MIT – with the stated goal of providing policy and market solutions to help manage the challenges of paying for gene
Key Takeaways
-
A new report by ICER and NEWDIGS at Tufts Medical Center provides policy and market solutions for helping manage the challenges of paying for gene therapies.
-
The report looked at the possibility of combining strategies, such as by “stacking” and “layering” discounts and warranties
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?